DNA damage in exfoliated cells and histopathological alterations in the urinary tract of mice exposed to cigarette smoke and treated with chemopreventive agents

Carcinogenesis

Volumn 34, Issue 1, 2013, Pages 183-189

  La maestra, Sebastiano ^a   Micale, Rosanna T ^a   De Flora, Silvio ^a   D'agostini, Francesco ^a   Ganchev, Gancho ^b   Iltcheva, Marietta ^b   Petkov, Nikolay ^b   Steele, Vernon E ^c   Balansky, Roumen ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b National Oncology Center Bulgaria   (Bulgaria)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; CIGARETTE SMOKE; INOSITOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; VORINOSTAT;

ANIMAL EXPERIMENT; ARTICLE; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DNA DAMAGE; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; KIDNEY INJURY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTICARCINOGENIC AGENTS; DNA DAMAGE; FEMALE; KIDNEY NEOPLASMS; MICE; PRECANCEROUS CONDITIONS; PREGNANCY; SMOKE; TOBACCO; URINARY BLADDER NEOPLASMS; URINARY TRACT;

EID: 84872125455     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs314     Document Type: Article

References (63)

1. American Cancer Society (2012). Cancer facts and figures. www.cancer.org/Research/CancerFactsFigures/ACSPC-031941.
2. International Agency for Research on Cancer. GLOBOCAN 2008. Cancer incidence, mortality and prevalence worldwide in 2008. http://globocan.iarc.fr/.
3. International Agency for Research on Cancer (2004) Tobacco smoke and involuntary smoking. IARC monographs on the evaluation of carcinogenic risks to humans. IARC, Lyon, 83.
4. Stewart, S.L. et al. (2008) Surveillance for cancers associated with tobacco use-United States, 1999-2004. MMWR. Surveill. Summ., 57, 1-33.
5. Ray, G. et al. (2010) Cigarette smoking as a cause of cancers other than lung cancer: an exploratory study using the Surveillance, Epidemiology, and End Results Program. Chest, 138, 491-499.
6. Brennan, P. et al. (2001) The contribution of cigarette smoking to bladder cancer in women (pooled European data). Cancer Causes Control, 12, 411-417.
7. Fleshner, N. et al. (1999) Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder. Cancer, 86, 2337-2345.
8. Gandini, S. et al. (2008) Tobacco smoking and cancer: a meta-analysis. Int. J. Cancer, 122, 155-164.
9. Tanaka, T. et al. (2011) Pathobiology and chemoprevention of bladder cancer. J. Oncol., 2011, 528353.
10. Balansky, R. et al. (2007) Potent carcinogenicity of cigarette smoke in mice exposed early in life. Carcinogenesis, 28, 2236-2243.
11. Balansky, R. et al. (2009) Prenatal N-acetylcysteine prevents cigarette smoke-induced lung cancer in neonatal mice. Carcinogenesis, 30, 1398-1401.
12. D'Agostini, F. et al. (2008) Preneoplastic and neoplastic lesions in the lung, liver and urinary tract of mice exposed to environmental cigarette smoke and UV light since birth. Int. J. Cancer, 123, 2497-2502.
13. Wattenberg, L.W. (1999) Chemoprevention of pulmonary carcinogenesis by myo-inositol. Anticancer Res., 19(5A), 3659-3661.
14. Zhang, Z. et al. (2000) A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53-independent efficacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents taxol or adriamycin. Cancer Res., 60, 901-907.
15. Witschi, H. (2000) Successful and not so successful chemoprevention of tobacco smoke-induced lung tumors. Exp. Lung Res., 26, 743-755.
16. Hecht, S.S. et al. (2002) Inhibition of lung tumorigenesis in A/J mice by N-acetyl-S-(N-2-phenethylthiocarbamoyl)-L-cysteine and myo-inositol, individually and in combination. Carcinogenesis, 23, 1455-1461.
17. Gunning, W.T. et al. (2000) Chemoprevention of vinyl carbamate-induced lung tumors in strain A mice. Exp. Lung Res., 26, 757-772.
18. Long, J. et al. (2009) Antitumor effects of a novel sulfur-containing hydroxamate histone deacetylase inhibitor H40. Int. J. Cancer, 124, 1235-1244.
19. Marks, P.A. (2007) Discovery and development of SAHA as an anticancer agent. Oncogene, 26, 1351-1356.
20. Qu, L. et al. (2010) Bexarotene: a promising anticancer agent. Cancer Chemother. Pharmacol., 65, 201-205.
21. Grubbs, C.J. et al. (2003) 9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers. Cancer Lett., 201, 17-24.
22. Lubet, R.A. et al. (2005) Efficacy of Targretin on methylnitrosoureainduced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis. Carcinogenesis, 26, 441-448.
23. Pereira, M.A. et al. (2006) Prevention of mouse lung tumors by targretin. Int. J. Cancer, 118, 2359-2362.
24. Wang, Y. et al. (2006) Organ-specific expression profiles of rat mammary gland, liver, and lung tissues treated with targretin, 9-cis retinoic acid, and 4-hydroxyphenylretinamide. Mol. Cancer Ther., 5, 1060-1072.
25. Zieleniak, A. et al. (2008) Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma. Arch. Immunol. Ther. Exp. (Warsz.), 56, 331-345.
26. Burgermeister, E. et al. (2008) PPARgamma and MEK Interactions in Cancer. PPAR Res., 2008, 309469.
27. Bundscherer, A. et al. (2009) Targeting the tumor stroma with peroxisome proliferator activated receptor (PPAR) agonists. Anticancer. Agents Med. Chem., 9, 816-821.
28. Mrówka, P. et al. (2008) Pioglitazone, a PPAR-gamma ligand, exerts cytostatic/ cytotoxic effects against cancer cells, that do not result from inhibition of proteasome. Acta Biochim. Pol., 55, 75-84.
29. Takeuchi, Y. et al. (2007) Suppression of N-nitrosobis(2-oxopropyl)amineinduced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor gamma. Carcinogenesis, 28, 1692-1696.
30. Osawa, E. et al. (2003) Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology, 124, 361-367.
31. Takano, S. et al. (2008) Pioglitazone, a ligand for peroxisome proliferatoractivated receptor-gamma acts as an inhibitor of colon cancer liver metastasis. Anticancer Res., 28(6A), 3593-3599.
32. Borbath, I. et al. (2007) The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver. Eur. J. Cancer, 43, 1755-1763.
33. Gontijo, A.M. et al. (2001) Single-cell gel (comet) assay detects primary DNA damage in nonneoplastic urothelial cells of smokers and ex-smokers. Cancer Epidemiol. Biomarkers Prev., 10, 987-993.
34. Fairbairn, D.W. et al. (1995) The comet assay: a comprehensive review. Mutat. Res., 339, 37-59.
35. Hellman, B. et al. (1995) The concepts of tail moment and tail inertia in the single cell gel electrophoresis assay. Mutat. Res., 336, 123-131.
36. Speit, G. et al. (2006) The comet assay: a sensitive genotoxicity test for the detection of DNA damage and repair. Methods Mol. Biol., 314, 275-286.
37. Tice, R.R. et al. (2000) Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen., 35, 206-221.
38. McGrath, M. et al. (2006) Hormonal and reproductive factors and the risk of bladder cancer in women. Am. J. Epidemiol., 163, 236-244.
39. Spangler, J.G. (1999) Smoking and hormone-related disorders. Prim. Care, 26, 499-511.
40. Okajima, E. et al. (1975) Effects of sex hormones on development of urinary bladder tumours in rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Urol. Res., 3, 73-79.
41. Tanahashi, N.K. et al. (1977) Effects of sex hormones on oncogenesis in rat urinary bladder by N-butyl-N-(4-hydroxybutyl)-nitrosamine. Int. J. Clin. Pharmacol. Biopharm., 15, 101-105.
42. Terada, S. et al. (1992) Effect of testosterone on the development of bladder tumors and calculi in female rats. Gynecol. Obstet. Invest., 34, 105-110.
43. Malkinson, A.M. (2004) Evidence that inflammation encourages pulmonary adenocarcinoma formation in mice: clinical implications. Chest, 125(5 Suppl), 154S-155S.
44. Takahashi, H. et al. (2010) Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell, 17, 89-97.
45. Martinez-Ferrer, M. et al. (2008) Role of nicotinic and estrogen signaling during experimental acute and chronic bladder inflammation. Am. J. Pathol., 172, 59-67.
46. Hardisty, J.F. et al. (2008) Histopathology of the urinary bladders of cynomolgus monkeys treated with PPAR agonists. Toxicol. Pathol., 36, 769-776.
47. Sato, K. et al. (2011) Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats. Toxicol. Appl. Pharmacol., 251, 234-244.
48. Lewis, J.D. et al. (2011) Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care, 34, 916-922.
49. Inoue, K. et al. (2001) Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Biochem. Biophys. Res. Commun., 287, 727-732.
50. Guan, Y.F. et al. (1999) Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia, 1, 330-339.
51. Brown, F.M. (2000) Urine cytology. It is still the gold standard for screening? Urol. Clin. North Am., 27, 25-37.
52. Reali, D. et al. (1987) Micronuclei in exfoliated urothelial cells and urine mutagenicity in smokers. Mutat. Res., 192, 145-149.
53. Lehucher-Michel, M.P. et al. (1995) The micronucleus assay in human exfoliated urothelial cells: effect of smoking. Mutagenesis, 10, 329-332.
54. Fracasso, M.E. et al. (2004) DNA breaks as measured by the alkaline comet assay in exfoliated cells as compared to voided urine cytology in the diagnosis of bladder cancer: a study of 105 subjects. Mutat. Res., 564, 57-64.
55. Kadlubar, F.F. et al. (1977) Hepatic microsomal N-glucuronidation and nucleic acid binding of N-hydroxy arylamines in relation to urinary bladder carcinogenesis. Cancer Res., 37, 805-814.
56. De Flora, S. et al. (1996) Smokers and urinary genotoxins: implications for selection of cohorts and modulation of endpoints in chemoprevention trials. J. Cell. Biochem. Suppl., 25, 92-98.
57. Curigliano, G. et al. (1996) Immunohistochemical quantitation of 4-aminobiphenyl-DNA adducts and p53 nuclear overexpression in T1 bladder cancer of smokers and nonsmokers. Carcinogenesis, 17, 911-916.
58. Izzotti, A. et al. (1999) Formation and persistence of nucleotide alterations in rats exposed whole-body to environmental cigarette smoke. Carcinogenesis, 20, 1499-1505.
59. Minozzi, M. et al. (2008) Treatment of hirsutism with myo-inositol: a prospective clinical study. Reprod. Biomed. Online, 17, 579-582.
60. Rothman, N. et al. (1997) Acidic urine pH is associated with elevated levels of free urinary benzidine and N-acetylbenzidine and urothelial cell DNA adducts in exposed workers. Cancer Epidemiol. Biomarkers Prev., 6, 1039-1042.
61. Alguacil, J. et al. (2011) Urinary pH, cigarette smoking and bladder cancer risk. Carcinogenesis, 32, 843-847.
62. Ziouzenkova, O. et al. (2008) Retinoid metabolism and nuclear receptor responses: New insights into coordinated regulation of the PPAR-RXR complex. FEBS Lett., 582, 32-38.
63. Tachibana, K. et al. (2008) The Role of PPARs in Cancer. PPAR Res., 2008, 102737.